aluminum has been researched along with Hepatitis A in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, S; Hamada, A; Kiyohara, T; Nakano, T; Tada, Y | 1 |
| Fukushima, S; Hamada, A; Ishii, K; Kiyohara, T; Nakano, T | 1 |
| Bock, J; Bovier, PA; Ebengo, TF; Frösner, G; Glaus, J; Herzog, C; Loutan, L | 1 |
| Beck, BR; Brönnimann, R; Hatz, C; Herzog, C | 1 |
| Herzog, C; Kasempimolporn, S; Mekmullica, J; Pancharoen, C; Thisyakorn, U; Wilde, H | 1 |
| Lyon, H; Prento, P | 1 |
| Malikova, TA | 1 |
1 trial(s) available for aluminum and Hepatitis A
| Article | Year |
|---|---|
Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.
Topics: Adult; Aged; Aluminum; Female; Hepatitis A; Hepatitis A Vaccines; Humans; Immunization, Secondary; Male; Middle Aged; Travel; Vaccines, Virosome | 2003 |
6 other study(ies) available for aluminum and Hepatitis A
| Article | Year |
|---|---|
Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.
Topics: Adult; Aluminum; East Asian People; Female; Hepatitis A; Hepatitis A Vaccines; Humans; Immunity; Immunization, Secondary; Male; Vaccines, Inactivated | 2023 |
Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries.
Topics: Adjuvants, Immunologic; Adult; Aged; Aluminum; Asian People; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis A; Hepatitis A Vaccines; Hepatitis Antibodies; Humans; Immunization, Secondary; Injections, Intramuscular; Male; Middle Aged; Travel; Vaccines, Inactivated; Young Adult | 2017 |
Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aluminum; Female; Follow-Up Studies; Hepatitis A; Hepatitis A Antibodies; Hepatitis A Vaccines; Human Experimentation; Humans; Immunoassay; Male; Middle Aged; Sex Factors; Time Factors; Vaccines, Virosome; Viral Vaccines; Young Adult | 2010 |
Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs.
Topics: Adolescent; Aluminum; Chemistry, Pharmaceutical; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Hepatitis A; Hepatitis A Antibodies; Hepatitis A Vaccines; Humans; Infant; Injections, Intradermal; Injections, Intramuscular; Male; Thailand | 2005 |
Artefactual staining of the peripheral zone of needle biopsies.
Topics: Aluminum; Biopsy, Needle; Cell Nucleus; Chemical and Drug Induced Liver Injury; Colloids; Coloring Agents; Connective Tissue; Cytoplasm; Hepatitis A; Humans; Iron; Liver; Liver Cirrhosis, Biliary; Methods; Nucleoproteins; Protein Denaturation; Rosaniline Dyes; Staining and Labeling; Stomach Ulcer | 1973 |
[Experience in use of spectral emission analysis in the study of metabolism of trace elements in patients with residual symptoms of Botkin's disease under health resort conditions].
Topics: Aluminum; Copper; Hepatitis A; Humans; Iron; Manganese; Silicon; Spectrum Analysis; Titanium; Trace Elements | 1969 |